Jagroop S Basraon, MD
Cardiac Electrophysiology · Clovis
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
- Since medical school
- 21 years
- Graduated 2005
On the public record
- 1 Medical Board action on record
Offices
6 locations · Community Foundation Medical Group · Fresno Community Hospital and Medical Center
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Basraon’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C10902 · Deceased
Licence status: Deceased · since 1948 · Johns Hopkins University School of Medicine.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
Public record actions
| 1983-01-12 | Board disciplineDiscipline | Surrender of license. · 06 1982600751 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$1,529,722
Medicare paid this office $1,529,722 for 2,151 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 208 | $252,728 | $1,215 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 208 | $170,861 | $411 |
| Insertion of heart rhythm monitor under skin | 46 | $163,123 | $3,546 |
| Return visit (30+ min) | 1,204 | $140,297 | $90 |
| Short return visit (20+ min) | 1,409 | $139,605 | $69 |
See all 50 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 208 | $252,728 | $1,215 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 208 | $170,861 | $411 |
| Insertion of heart rhythm monitor under skin | 46 | $163,123 | $3,546 |
| Return visit (30+ min) | 1,204 | $140,297 | $90 |
| Short return visit (20+ min) | 1,409 | $139,605 | $69 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 643 | $101,082 | $152 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 123 | $85,418 | $694 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 134 | $72,584 | $84 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 86 | $60,900 | $700 |
| Long return visit (40+ min) | 268 | $39,892 | $138 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 527 | $33,042 | $32 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,502 | $23,637 | $11 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 31 | $20,498 | $621 |
| New patient visit (45+ min) | 155 | $17,981 | $116 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 267 | $15,565 | $58 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 44 | $15,162 | $345 |
| Insertion of permanent leadless pacemaker using imaging guidance | 51 | $14,842 | $291 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 152 | $14,478 | $43 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $13,195 | $135 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 38 | $13,077 | $344 |
| Destruction of heart conduction tissue to create heart block | 26 | $11,704 | $433 |
| Insertion of implantable defibrillator system | 16 | $11,144 | $656 |
| Ultrasound of heart with probe in esophagus, with report | 124 | $10,664 | $82 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 20 | $8,909 | $228 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 34 | $6,546 | $193 |
| External shock to heart to regulate heart beat | 71 | $6,299 | $82 |
| New patient visit (60+ min) | 38 | $5,992 | $158 |
| Injection, regadenoson, 0.1 mg | 246 | $5,831 | None |
| Evaluation of cardiac rhythm monitor system | 136 | $5,661 | $24 |
| Ultrasound of both sides of head and neck blood flow | 28 | $4,499 | $161 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 81 | $4,305 | $53 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 12 | $4,115 | $343 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,640 | $93 |
| Programming of heart rhythm stimulation after drug infusion | 61 | $3,233 | $52 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 42 | $3,023 | $36 |
| Removal and replacement of dual lead permanent pacemaker | 12 | $2,628 | $219 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 124 | $2,373 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $2,005 | $51 |
| Removal of heart rhythm monitor from under the skin | 27 | $1,481 | $55 |
| Ultrasound of heart blood flow, valves and chambers | 34 | $1,389 | $41 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 34 | $637 | $19 |
| Ultrasound of heart, follow-up | 24 | $486 | $19 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 19 | $363 | $18 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 28 | $285 | $9 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 94 | $234 | $2 |
| Injection, aminophyllin, up to 250 mg | 39 | $233 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 36 | $222 | $6 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 13 | $210 | $16 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 19 | $203 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 21 | $116 | $6 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 24 | More than 56% of doctors who do this |
| Leg revascularization (restoring blood flow) | 1-10 | None |
| Pacemaker insertion or repair | 127 | More than 99% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of permanent leadless pacemaker using imaging guidance | 32 | 58 | 44 | 32 | 36 | 51 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 32 | 35 | 48 | 36 | 41 | 38 |
| Insertion of heart rhythm monitor under skin | 17 | 30 | 40 | 38 | 28 | 46 |
| Removal of heart rhythm monitor from under the skin | 13 | – | 18 | 25 | 33 | 27 |
| Insertion of implantable defibrillator system | 11 | 19 | 20 | 12 | – | 17 |
| Removal and replacement of dual lead permanent pacemaker | – | – | 15 | 18 | 14 | 12 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
2,151 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 18% · Women 50% · Also on Medicaid 14% · Health risk score 1.55. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 1.8.
Conditions among them: High blood pressure 75% · Coronary heart disease 59% · Atrial fibrillation 55% · Diabetes 39% · Heart failure 36% · Chronic kidney disease 35% · Depression 17% · Cancer 16% · COPD 15% · Stroke 15% · Dementia 7%.
The office billed $6,688,031, Medicare allowed $1,992,308 and paid $1,529,722; for 13,204 services of 82 kinds; $6,066 of it was for drugs given in the office and $1,523,656 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,151 | 13,204 | 77 | 1.55 | $6,688,031 | $1,529,722 |
| 2023 | 1,869 | 11,407 | 76 | 1.50 | $4,900,617 | $1,158,924 |
| 2022 | 1,696 | 11,440 | 76 | 1.53 | $5,083,923 | $1,225,472 |
| 2021 | 1,457 | 11,212 | 76 | 1.56 | $5,914,909 | $1,605,349 |
| 2020 | 1,241 | 8,114 | 77 | 1.75 | $3,107,534 | $868,139 |
| 2019 | 1,084 | 7,042 | 76 | 1.73 | $1,647,698 | $563,220 |
| 2018 | 865 | 5,873 | 77 | 1.77 | $1,370,531 | $559,379 |
| 2017 | 880 | 4,579 | 77 | 2.11 | $1,037,844 | $392,847 |
| 2016 | 1,259 | 4,932 | 76 | 1.96 | $1,248,889 | $403,166 |
| 2015 | 362 | 1,743 | 77 | 1.70 | $477,755 | $166,890 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 50 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 204 | $255,550 | $1,241 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 204 | $171,236 | $416 |
| Short return visit (20+ min) | 1,202 | $123,768 | $66 |
| Return visit (30+ min) | 757 | $94,244 | $99 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 545 | $88,815 | $158 |
| Injection, regadenoson, 0.1 mg | 233 | $39,803 | None |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 38 | $28,255 | $744 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 438 | $26,081 | $29 |
| Long return visit (40+ min) | 162 | $25,835 | $137 |
| New patient visit (45+ min) | 205 | $24,869 | $121 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,362 | $21,536 | $11 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 46 | $17,272 | $375 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 23 | $16,885 | $734 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 275 | $16,130 | $57 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 41 | $15,924 | $388 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 112 | $15,908 | $21 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 24 | $15,737 | $656 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $12,588 | $138 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 132 | $12,570 | $43 |
| New patient visit (60+ min) | 70 | $11,982 | $171 |
| Insertion of permanent leadless pacemaker using imaging guidance | 36 | $11,208 | $311 |
| Destruction of heart conduction tissue to create heart block | 20 | $9,378 | $447 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $6,267 | $96 |
| External shock to heart to regulate heart beat | 62 | $5,921 | $85 |
| Ultrasound of heart with probe in esophagus, with report | 68 | $5,853 | $81 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 26 | $4,352 | $167 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 80 | $4,223 | $52 |
| Evaluation of cardiac rhythm monitor system | 109 | $3,967 | $24 |
| Removal and replacement of dual lead permanent pacemaker | 14 | $3,269 | $234 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 45 | $3,139 | $35 |
| Telephone medical discussion with physician, 11-20 minutes | 40 | $2,806 | $70 |
| Removal of heart rhythm monitor from under the skin | 33 | $1,929 | $58 |
| Insertion of heart rhythm monitor under skin | 28 | $1,927 | $69 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 93 | $1,736 | $19 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 55 | $1,170 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 26 | $1,129 | $43 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 93 | $925 | $10 |
| Programming of heart rhythm stimulation after drug infusion | 12 | $809 | $67 |
| Electrocardiogram (ecg) 2-day continuous | 47 | $688 | $15 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 46 | $634 | $14 |
| Heart rhythm recording of continous external ekg over 8-15 days | 55 | $571 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $531 | $20 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 23 | $473 | $21 |
| Ultrasound of heart, follow-up | 21 | $452 | $20 |
| Injection, aminophyllin, up to 250 mg | 43 | $289 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 31 | $208 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 69 | $173 | $2 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $156 | $13 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician | 13 | $138 | $11 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 15 | $85 | $6 |
2022: 45 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 252 | $313,923 | $1,241 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 253 | $210,058 | $414 |
| Short return visit (20+ min) | 1,073 | $109,643 | $70 |
| Return visit (30+ min) | 801 | $100,956 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 517 | $85,454 | $162 |
| Injection, regadenoson, 0.1 mg | 272 | $53,411 | None |
| New patient visit (45+ min) | 345 | $42,400 | $123 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 433 | $26,213 | $31 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 29 | $25,645 | $884 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,368 | $22,720 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 306 | $18,662 | $59 |
| New patient visit (60+ min) | 99 | $17,472 | $176 |
| Long return visit (40+ min) | 111 | $16,184 | $132 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 24 | $15,873 | $661 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 115 | $15,521 | $21 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 36 | $14,581 | $405 |
| Insertion of permanent leadless pacemaker using imaging guidance | 32 | $11,836 | $370 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $11,754 | $161 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 131 | $11,319 | $45 |
| Insertion of implantable defibrillator system | 12 | $8,741 | $728 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 23 | $8,691 | $378 |
| Telephone medical discussion with physician, 11-20 minutes | 89 | $6,777 | $74 |
| Ultrasound of heart with probe in esophagus, with report | 62 | $5,753 | $87 |
| External shock to heart to regulate heart beat | 51 | $4,542 | $84 |
| Evaluation of cardiac rhythm monitor system | 118 | $4,473 | $24 |
| Removal and replacement of dual lead permanent pacemaker | 18 | $4,370 | $243 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 20 | $3,995 | $200 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,372 | $80 |
| Insertion of heart rhythm monitor under skin | 38 | $2,650 | $70 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 102 | $1,988 | $19 |
| Removal of heart rhythm monitor from under the skin | 25 | $1,722 | $69 |
| Programming of heart rhythm stimulation after drug infusion | 20 | $1,705 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 30 | $1,700 | $57 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 23 | $1,670 | $36 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 56 | $1,239 | $22 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 102 | $1,176 | $11 |
| Ultrasound of heart blood flow, valves and chambers | 20 | $885 | $44 |
| Programming of dual lead pacemaker system | 15 | $659 | $26 |
| Heart rhythm recording of continous external ekg over 8-15 days | 56 | $658 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $415 | $21 |
| Evaluation of implantable heart and blood vessel monitoring system | 11 | $413 | $20 |
| Electrocardiogram (ecg) 2-day continuous | 25 | $367 | $15 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 25 | $351 | $14 |
| Injection, aminophyllin, up to 250 mg | 38 | $276 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 65 | $171 | $3 |
2021: 55 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 295 | $385,025 | $1,292 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 296 | $253,585 | $424 |
| Return visit (30+ min) | 1,144 | $211,646 | $101 |
| Insertion of heart rhythm monitor under skin | 40 | $180,146 | $4,504 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 475 | $82,481 | $167 |
| Injection, regadenoson, 0.1 mg | 315 | $61,913 | None |
| New patient visit (45+ min) | 252 | $32,994 | $131 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 384 | $30,725 | $40 |
| Long return visit (40+ min) | 159 | $26,613 | $141 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 27 | $24,597 | $911 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,158 | $22,225 | $12 |
| New patient visit (60+ min) | 118 | $21,413 | $181 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 30 | $20,397 | $680 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 331 | $20,336 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 110 | $19,731 | $166 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 48 | $16,825 | $351 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 111 | $16,600 | $21 |
| Destruction of heart conduction tissue to create heart block | 30 | $14,446 | $482 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 56 | $13,505 | $241 |
| Insertion of implantable defibrillator system | 20 | $13,356 | $668 |
| Insertion of permanent leadless pacemaker using imaging guidance | 44 | $13,006 | $296 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 118 | $12,607 | $53 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 24 | $10,004 | $417 |
| Critical care, first 30-74 minutes | 21 | $8,156 | $181 |
| External shock to heart to regulate heart beat | 64 | $6,602 | $90 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 17 | $6,487 | $382 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 12 | $6,164 | $514 |
| Short return visit (20+ min) | 75 | $5,655 | $74 |
| Ultrasound of heart with probe in esophagus, with report | 61 | $5,571 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $5,304 | $86 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 23 | $4,395 | $191 |
| Programming of heart rhythm stimulation after drug infusion | 40 | $4,360 | $109 |
| Evaluation of cardiac rhythm monitor system | 93 | $4,332 | $34 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 24 | $4,123 | $86 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 39 | $3,735 | $96 |
| Removal and replacement of dual lead permanent pacemaker | 15 | $3,153 | $210 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 30 | $2,930 | $98 |
| Removal and replacement of multiple lead defibrillator | 11 | $2,597 | $236 |
| Evaluation of implantable heart and blood vessel monitoring system | 46 | $1,881 | $31 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 69 | $1,410 | $20 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,350 | $104 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,242 | $78 |
| Removal of heart rhythm monitor from under the skin | 18 | $1,172 | $65 |
| Programming of dual lead pacemaker system | 33 | $1,170 | $25 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 20 | $1,108 | $55 |
| Ultrasound of heart blood flow, valves and chambers | 23 | $1,070 | $47 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 69 | $886 | $13 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 31 | $682 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 23 | $506 | $22 |
| Heart rhythm recording of continous external ekg over 8-15 days | 30 | $379 | $13 |
| Injection, aminophyllin, up to 250 mg | 53 | $364 | None |
| Ultrasound of heart, follow-up | 17 | $356 | $21 |
| Electrocardiogram (ecg) 2-day continuous | 18 | $343 | $17 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 18 | $316 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 64 | $167 | $3 |
2020: 47 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 108 | $142,008 | $1,315 |
| Return visit (30+ min) | 682 | $92,136 | $87 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 109 | $91,854 | $421 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 376 | $65,120 | $167 |
| Short return visit (20+ min) | 629 | $49,239 | $56 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 44 | $40,876 | $929 |
| Injection, regadenoson, 0.1 mg | 132 | $24,730 | None |
| New patient visit (45+ min) | 194 | $24,671 | $127 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 31 | $21,665 | $677 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 328 | $20,283 | $34 |
| Insertion of permanent leadless pacemaker using imaging guidance | 58 | $20,159 | $348 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $19,930 | $167 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 76 | $19,396 | $246 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 891 | $18,104 | $13 |
| New patient visit (60+ min) | 96 | $16,009 | $167 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 35 | $13,609 | $389 |
| Insertion of implantable defibrillator system | 19 | $13,304 | $700 |
| Long return visit (40+ min) | 83 | $11,541 | $119 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 78 | $11,040 | $22 |
| Critical care, first 30-74 minutes | 38 | $9,768 | $184 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 24 | $8,893 | $371 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $8,336 | $82 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 140 | $8,250 | $59 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 98 | $7,778 | $49 |
| Ultrasound of heart with probe in esophagus, with report | 78 | $7,214 | $88 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 17 | $6,277 | $349 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 48 | $5,868 | $122 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 11 | $5,746 | $522 |
| Programming of heart rhythm stimulation after drug infusion | 40 | $5,526 | $132 |
| Destruction of heart conduction tissue to create heart block | 12 | $5,480 | $457 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 24 | $4,554 | $95 |
| External shock to heart to regulate heart beat | 43 | $4,458 | $93 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 37 | $3,602 | $97 |
| Insertion of heart rhythm monitor under skin | 30 | $2,158 | $72 |
| Evaluation of implantable heart and blood vessel monitoring system | 52 | $1,976 | $27 |
| Programming of dual lead pacemaker system | 39 | $1,923 | $34 |
| External ekg recording for more than 48 hours up to 21 days | 83 | $1,861 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 83 | $1,832 | $22 |
| Evaluation of cardiac rhythm monitor system | 54 | $1,561 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 23 | $1,313 | $57 |
| Programming of multiple lead implantable defibrillator system | 11 | $872 | $51 |
| Programming of single lead implantable defibrillator system | 11 | $683 | $46 |
| Programming of single lead pacemaker system | 14 | $590 | $35 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 23 | $516 | $22 |
| Electrocardiogram (ecg) 2-day continuous | 23 | $509 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 74 | $207 | $3 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 16 | $180 | $11 |
2019: 46 services
| Return visit (30+ min) | 577 | $78,329 | $84 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 44 | $55,130 | $1,253 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 311 | $52,803 | $164 |
| Short return visit (20+ min) | 492 | $32,117 | $55 |
| New patient visit (45+ min) | 207 | $26,704 | $129 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 55 | $21,982 | $400 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 44 | $21,875 | $249 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 913 | $21,106 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $17,816 | $163 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 19 | $17,311 | $911 |
| Injection, regadenoson, 0.1 mg | 92 | $16,740 | None |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 24 | $16,166 | $674 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 235 | $15,015 | $32 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 32 | $13,100 | $409 |
| Insertion of permanent leadless pacemaker using imaging guidance | 32 | $12,050 | $377 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 44 | $10,581 | $240 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 55 | $10,505 | $95 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 68 | $10,326 | $21 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $9,551 | $85 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 90 | $8,283 | $47 |
| Long return visit (40+ min) | 58 | $8,145 | $115 |
| Insertion of implantable defibrillator system | 11 | $7,877 | $716 |
| Destruction of heart conduction tissue to create heart block | 14 | $7,683 | $480 |
| Ultrasound of heart with probe in esophagus, with report | 69 | $6,473 | $89 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 106 | $6,126 | $56 |
| Critical care, first 30-74 minutes | 17 | $3,985 | $181 |
| Evaluation of cardiac rhythm monitor system | 69 | $3,530 | $28 |
| Programming of heart rhythm stimulation after drug infusion | 27 | $3,497 | $130 |
| External shock to heart to regulate heart beat | 38 | $3,461 | $89 |
| New patient visit (30+ min) | 34 | $2,698 | $79 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 22 | $2,636 | $120 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 27 | $2,571 | $95 |
| New patient visit (60+ min) | 15 | $2,562 | $171 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 26 | $1,572 | $60 |
| Programming of dual lead pacemaker system | 27 | $1,384 | $33 |
| Insertion of heart rhythm monitor under skin | 17 | $1,229 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,074 | $60 |
| Programming of multiple lead implantable defibrillator system | 13 | $1,054 | $48 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 39 | $860 | $22 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 36 | $797 | $21 |
| Electrocardiogram (ecg) 2-day continuous | 36 | $791 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 39 | $789 | $20 |
| Removal of heart rhythm monitor from under the skin | 13 | $780 | $60 |
| Evaluation of implantable heart and blood vessel monitoring system | 21 | $537 | $19 |
| Ultrasound of heart blood flow, valves and chambers | 20 | $316 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 66 | $177 | $3 |
2018: 43 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 56 | $77,933 | $1,392 |
| Return visit (30+ min) | 362 | $61,388 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 284 | $54,952 | $185 |
| New patient visit (45+ min) | 248 | $34,735 | $140 |
| Short return visit (20+ min) | 393 | $31,423 | $61 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 58 | $26,801 | $462 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 56 | $21,281 | $190 |
| Injection, regadenoson, 0.1 mg | 110 | $19,363 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 669 | $19,264 | $14 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 25 | $18,184 | $727 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $18,007 | $186 |
| Implantation or replacement of permanent ventricular pacemaker | 44 | $15,533 | $353 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 58 | $12,362 | $107 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 22 | $9,952 | $452 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $9,856 | $95 |
| Critical care, first 30-74 minutes | 23 | $9,710 | $202 |
| Insertion of implantable defibrillator system | 11 | $9,023 | $820 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 29 | $8,294 | $286 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 126 | $7,761 | $34 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 117 | $7,300 | $62 |
| Long return visit (40+ min) | 39 | $6,463 | $129 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 55 | $6,249 | $23 |
| Implantation patient-activated heart monitoring device | 30 | $5,899 | $197 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 54 | $4,969 | $47 |
| Programming of heart rhythm stimulation after drug infusion | 30 | $4,220 | $141 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 68 | $3,549 | $52 |
| New patient visit (60+ min) | 18 | $3,268 | $182 |
| Evaluation of cardiac rhythm monitor system | 58 | $3,109 | $29 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 29 | $3,004 | $104 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 13 | $2,831 | $218 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 86 | $2,088 | $24 |
| Electrocardiogram (ecg) 2-day continuous | 85 | $2,046 | $24 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,928 | $64 |
| Ultrasound of heart with probe in esophagus, with report | 21 | $1,906 | $91 |
| Programming of dual lead pacemaker system | 34 | $1,541 | $35 |
| Programming of multiple lead implantable defibrillator system | 12 | $1,400 | $58 |
| New patient visit (30+ min) | 13 | $1,198 | $92 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 34 | $820 | $24 |
| External ekg recording for more than 48 hours up to 21 days | 34 | $813 | $24 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $677 | $52 |
| Evaluation of implantable heart and blood vessel monitoring system | 14 | $364 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $349 | $25 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $67 | $3 |
2017: 45 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 63 | $74,649 | $1,185 |
| Return visit (30+ min) | 314 | $39,592 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 196 | $37,141 | $182 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $19,248 | $162 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 63 | $18,606 | $149 |
| New patient visit (45+ min) | 136 | $17,190 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $16,837 | $85 |
| Injection, regadenoson, 0.1 mg | 73 | $12,713 | None |
| Short return visit (20+ min) | 189 | $12,643 | $59 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 454 | $12,050 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 230 | $11,582 | $50 |
| Critical care, first 30-74 minutes | 19 | $10,067 | $180 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 14 | $9,258 | $661 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 77 | $7,675 | $59 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 18 | $5,751 | $320 |
| Implantation or replacement of permanent ventricular pacemaker | 18 | $5,583 | $310 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 79 | $5,098 | $62 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $4,469 | $406 |
| Long return visit (40+ min) | 26 | $3,644 | $118 |
| New patient visit (60+ min) | 21 | $3,531 | $168 |
| Implantation patient-activated heart monitoring device | 20 | $3,335 | $167 |
| Programming of multiple lead implantable defibrillator system | 18 | $2,923 | $55 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $2,734 | $228 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 33 | $2,734 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 68 | $2,552 | $30 |
| Programming of heart rhythm stimulation after drug infusion | 17 | $2,190 | $129 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 29 | $2,156 | $51 |
| Ultrasound of heart with probe in esophagus, with report | 24 | $2,062 | $82 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 83 | $1,835 | $21 |
| Electrocardiogram (ecg) 2-day continuous | 83 | $1,792 | $21 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 18 | $1,708 | $95 |
| Programming of dual lead pacemaker system | 35 | $1,651 | $33 |
| External shock to heart to regulate heart beat | 19 | $1,573 | $83 |
| Evaluation of cardiac rhythm monitor system | 35 | $1,367 | $30 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 140 | $1,003 | $6 |
| Return visit (30+ min) | 11 | $662 | $60 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $549 | $46 |
| Evaluation of implantable heart and blood vessel monitoring system | 17 | $451 | $17 |
| Ultrasound of heart, follow-up | 19 | $401 | $21 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 13 | $286 | $22 |
| External ekg recording for more than 48 hours up to 21 days | 13 | $280 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $261 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 32 | $89 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 14 | $84 | $6 |
| Infusion, normal saline solution , 1000 cc | 22 | $33 | None |
2016: 37 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 70 | $81,124 | $1,159 |
| Return visit (30+ min) | 310 | $49,923 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 156 | $33,914 | $186 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 34 | $23,234 | $683 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 71 | $21,921 | $155 |
| New patient visit (45+ min) | 141 | $18,617 | $132 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $14,601 | $164 |
| Injection, regadenoson, 0.1 mg | 77 | $13,009 | None |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 39 | $12,488 | $320 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 372 | $10,950 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $10,533 | $84 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 17 | $9,568 | $504 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 183 | $9,517 | $52 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 20 | $7,990 | $399 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 773 | $6,897 | $7 |
| Programming of heart rhythm stimulation after drug infusion | 49 | $6,278 | $128 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 85 | $5,345 | $61 |
| New patient visit (60+ min) | 31 | $5,223 | $168 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 45 | $4,244 | $94 |
| Long return visit (40+ min) | 31 | $3,904 | $118 |
| Implantation patient-activated heart monitoring device | 18 | $3,299 | $183 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 122 | $2,936 | $22 |
| Electrocardiogram (ecg) 2-day continuous | 122 | $2,781 | $20 |
| Ultrasound of heart with probe in esophagus, with report | 27 | $2,549 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,046 | $58 |
| Programming of multiple lead implantable defibrillator system | 14 | $1,957 | $53 |
| External shock to heart to regulate heart beat | 14 | $1,708 | $100 |
| Programming of dual lead pacemaker system | 30 | $1,389 | $35 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 39 | $1,262 | $26 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 18 | $1,211 | $22 |
| Evaluation of cardiac rhythm monitor system | 22 | $818 | $26 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 11 | $615 | $51 |
| Evaluation of implantable heart and blood vessel monitoring system | 12 | $397 | $17 |
| Ultrasound of heart, follow-up | 18 | $380 | $21 |
| Infusion, normal saline solution , 1000 cc | 71 | $110 | None |
| Injection, aminophyllin, up to 250 mg | 12 | $75 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 27 | $68 | $3 |
2015: 24 services
| Return visit (30+ min) | 181 | $25,434 | $87 |
| New patient visit (45+ min) | 140 | $18,593 | $133 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 76 | $15,213 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $12,331 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $12,291 | $162 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 15 | $10,150 | $677 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 17 | $5,381 | $317 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $4,959 | $413 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $4,497 | $409 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 195 | $4,000 | $14 |
| Injection, regadenoson, 0.1 mg | 19 | $3,146 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 56 | $2,984 | $51 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 34 | $2,307 | $61 |
| Ultrasound of heart with probe in esophagus, with report | 22 | $2,268 | $99 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 12 | $2,254 | $98 |
| Electrocardiogram (ecg) 2-day continuous | 71 | $1,764 | $22 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 71 | $1,727 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,630 | $58 |
| External shock to heart to regulate heart beat | 14 | $1,340 | $96 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 14 | $1,327 | $95 |
| Short return visit (20+ min) | 16 | $948 | $59 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 11 | $623 | $42 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $206 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $58 | $3 |
Medicaid work
$2,400 in 2024
Medicaid paid $2,400 for 468 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 138 | $837 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 14 | $592 |
| Short return visit (20+ min) | 133 | $535 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 157 | $433 |
| Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead pacemaker system, or leadless pacemaker system | 26 | $4 |
| 2024 | 468 | 5 | 34 | $2,400 |
| 2023 | 719 | 7 | 32 | $1,838 |
| 2022 | 321 | 3 | 22 | $472 |
| 2021 | 26 | 2 | 13 | $125 |
| 2020 | 13 | 1 | 13 | $0 |
| 2019 | 30 | 1 | 18 | $37 |
| 2018 | 280 | 4 | 33 | $1,075 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 46 | $783 |
| Short return visit (20+ min) | 267 | $445 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 259 | $370 |
| CARDIOVASCULAR STRESS TEST | 12 | $129 |
| Return visit (30+ min) | 93 | $55 |
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 12 | $30 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 30 | $26 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 164 | $310 |
| Short return visit (20+ min) | 131 | $162 |
| Return visit (30+ min) | 26 | $0 |
2021
| Return visit (30+ min) | 13 | $96 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 13 | $29 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 13 | $0 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 30 | $37 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 188 | $532 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 25 | $411 |
| Short return visit (20+ min) | 52 | $132 |
| New patient visit (45+ min) | 15 | $0 |
Drugs they prescribed that Part D paid
$2,661,127
Pharmacies billed $2,661,127 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
8,720 generic and 2,341 brand-name prescriptions · $2,661,127 in drug cost · 67 antibiotic prescriptions to 62 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 1,657 | $1,905,041 | $1,150 |
| Xarelto | 294 | $327,159 | $1,113 |
| Entresto | 144 | $148,589 | $1,032 |
| Repatha Sureclick | 48 | $60,230 | $1,255 |
| Metoprolol | 1,499 | $23,523 | $16 |
See all 55 drugs
| Eliquis | 1,657 | $1,905,041 | $1,150 |
| Xarelto | 294 | $327,159 | $1,113 |
| Entresto | 144 | $148,589 | $1,032 |
| Repatha Sureclick | 48 | $60,230 | $1,255 |
| Metoprolol | 1,499 | $23,523 | $16 |
| Flecainide Acetate | 493 | $20,702 | $42 |
| Amiodarone | 364 | $13,465 | $37 |
| Diltiazem 24hr Er (Cd) | 422 | $12,226 | $29 |
| Ranolazine Er | 61 | $7,134 | $117 |
| Atorvastatin | 639 | $6,864 | $11 |
| Propafenone Hcl Er | 24 | $6,845 | $285 |
| Diltiazem | 337 | $5,847 | $17 |
| Carvedilol | 625 | $5,379 | $9 |
| Icosapent Ethyl | 12 | $5,370 | $448 |
| Propafenone | 90 | $5,335 | $59 |
| Hydralazine | 419 | $4,816 | $11 |
| Midodrine | 75 | $4,525 | $60 |
| Enoxaparin | 49 | $3,505 | $72 |
| Losartan | 337 | $3,038 | $9 |
| Spironolactone | 291 | $2,900 | $10 |
| Diltiazem 12hr Er | 12 | $2,897 | $241 |
| Amlodipine Besylate | 457 | $2,767 | $6 |
| Ezetimibe | 79 | $2,745 | $35 |
| Lisinopril | 328 | $2,575 | $8 |
| Rosuvastatin | 156 | $2,392 | $15 |
| Potassium Chloride | 100 | $2,314 | $23 |
| Metoprolol | 359 | $2,005 | $6 |
| Nitroglycerin | 115 | $1,906 | $17 |
| Pacerone | 11 | $1,855 | $169 |
| Furosemide | 315 | $1,722 | $5 |
| Valsartan | 50 | $1,660 | $33 |
| Isosorbide Mononitrate Er | 116 | $1,426 | $12 |
| Clopidogrel | 114 | $1,353 | $12 |
| Sotalol | 80 | $1,151 | $14 |
| Pravastatin | 65 | $869 | $13 |
| Nebivolol | 12 | $713 | $59 |
| Warfarin | 58 | $640 | $11 |
| Atenolol | 82 | $524 | $6 |
| Cartia Xt | 42 | $522 | $12 |
| Hydrochlorothiazide | 112 | $396 | $4 |
| Bisoprolol | 21 | $329 | $16 |
| Benazepril | 28 | $319 | $11 |
| Diltiazem 24hr Er | 14 | $318 | $23 |
| Verapamil Er | 15 | $312 | $21 |
| Chlorthalidone | 13 | $291 | $22 |
| Olmesartan Medoxomil | 18 | $266 | $15 |
| Pantoprazole | 17 | $260 | $15 |
| Simvastatin | 39 | $259 | $7 |
| Bumetanide | 15 | $212 | $14 |
| Klor-Con 10 | 18 | $189 | $10 |
| Propranolol | 11 | $187 | $17 |
| Fludrocortisone Acetate | 15 | $140 | $9 |
| Lisinopril-Hydrochlorothiazide | 11 | $123 | $11 |
| Cephalexin | 25 | $101 | $4 |
| Clindamycin | 38 | $98 | $3 |
Year by year
| 2024 | 11,061 | 1,698 | None | 21% | $2,661,127 |
| 2023 | 7,779 | 1,287 | None | 21% | $1,790,962 |
| 2022 | 6,494 | 1,046 | 1% (32) | 21% | $1,415,566 |
| 2021 | 5,860 | 916 | 1% (76) | 21% | $1,153,528 |
| 2020 | 5,084 | 758 | 1% (55) | 22% | $890,556 |
| 2019 | 5,479 | 671 | 1% (34) | 21% | $679,844 |
| 2018 | 4,732 | 489 | 1% (24) | 23% | $474,862 |
| 2017 | 3,236 | 351 | None | 34% | $312,460 |
| 2016 | 2,139 | 270 | None | 30% | $206,773 |
| 2015 | 709 | 150 | None | 27% | $66,326 |
| 2013 | 38 | None | 0% (0) | 34% | $1,201 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 48 drugs
| Eliquis | 1,230 | $1,334,344 | $1,085 |
| Xarelto | 215 | $241,317 | $1,122 |
| Metoprolol | 1,206 | $24,626 | $20 |
| Entresto | 13 | $19,205 | $1,477 |
| Flecainide Acetate | 286 | $18,767 | $66 |
| Repatha Sureclick | 14 | $14,328 | $1,023 |
| Diltiazem 24hr Er (Cd) | 323 | $11,756 | $36 |
| Amiodarone | 252 | $10,453 | $41 |
| Atorvastatin | 422 | $8,022 | $19 |
| Midodrine | 74 | $6,761 | $91 |
| Diltiazem | 258 | $6,330 | $25 |
| Carvedilol | 444 | $6,051 | $14 |
| Amlodipine Besylate | 467 | $5,107 | $11 |
| Ranolazine Er | 37 | $4,696 | $127 |
| Hydralazine | 264 | $4,581 | $17 |
| Losartan | 240 | $4,329 | $18 |
| Enoxaparin | 41 | $3,985 | $97 |
| Propafenone Hcl Er | 11 | $3,214 | $292 |
| Rosuvastatin | 91 | $2,483 | $27 |
| Metoprolol | 255 | $2,232 | $9 |
| Valsartan | 29 | $2,185 | $75 |
| Potassium Chloride | 68 | $2,111 | $31 |
| Isosorbide Mononitrate Er | 67 | $2,029 | $30 |
| Spironolactone | 144 | $2,024 | $14 |
| Lisinopril | 228 | $2,015 | $9 |
| Furosemide | 220 | $1,758 | $8 |
| Nitroglycerin | 78 | $1,527 | $20 |
| Ezetimibe | 23 | $1,452 | $63 |
| Propafenone | 18 | $975 | $54 |
| Clopidogrel | 54 | $930 | $17 |
| Cartia Xt | 34 | $831 | $24 |
| Sotalol | 25 | $667 | $27 |
| Nebivolol | 11 | $630 | $57 |
| Atenolol | 85 | $606 | $7 |
| Olmesartan Medoxomil | 16 | $544 | $34 |
| Pravastatin | 44 | $534 | $12 |
| Fludrocortisone Acetate | 20 | $526 | $26 |
| Simvastatin | 25 | $490 | $20 |
| Diltiazem 24hr Er | 17 | $470 | $28 |
| Bisoprolol | 15 | $459 | $31 |
| Hydrochlorothiazide | 105 | $436 | $4 |
| Chlorthalidone | 14 | $379 | $27 |
| Omeprazole | 27 | $350 | $13 |
| Klor-Con 10 | 11 | $332 | $30 |
| Warfarin | 17 | $266 | $16 |
| Benazepril | 19 | $214 | $11 |
| Verapamil | 11 | $183 | $17 |
| Cephalexin | 26 | $110 | $4 |
2022: 44 drugs
| Eliquis | 1,063 | $1,051,824 | $989 |
| Xarelto | 179 | $180,571 | $1,009 |
| Metoprolol | 1,043 | $22,974 | $22 |
| Flecainide Acetate | 240 | $17,887 | $75 |
| Diltiazem 24hr Er (Cd) | 326 | $13,854 | $42 |
| Amiodarone | 208 | $10,943 | $53 |
| Midodrine | 55 | $10,375 | $189 |
| Atorvastatin | 332 | $5,188 | $16 |
| Propafenone Hcl Er | 13 | $4,715 | $363 |
| Diltiazem | 142 | $3,977 | $28 |
| Carvedilol | 377 | $3,934 | $10 |
| Amlodipine Besylate | 395 | $3,296 | $8 |
| Ranolazine Er | 13 | $2,610 | $201 |
| Losartan | 219 | $2,593 | $12 |
| Rosuvastatin | 51 | $2,523 | $49 |
| Ezetimibe | 30 | $2,523 | $84 |
| Hydralazine | 140 | $2,216 | $16 |
| Potassium Chloride | 63 | $2,198 | $35 |
| Lisinopril | 255 | $2,078 | $8 |
| Isosorbide Mononitrate Er | 48 | $1,631 | $34 |
| Digoxin | 16 | $1,526 | $95 |
| Nitroglycerin | 62 | $1,466 | $24 |
| Metoprolol | 157 | $1,345 | $9 |
| Diltiazem 24hr Er | 32 | $1,342 | $42 |
| Spironolactone | 113 | $1,268 | $11 |
| Valsartan | 24 | $1,118 | $47 |
| Furosemide | 151 | $1,036 | $7 |
| Propafenone | 15 | $1,032 | $69 |
| Olmesartan Medoxomil | 18 | $940 | $52 |
| Clopidogrel | 49 | $759 | $15 |
| Pravastatin | 42 | $670 | $16 |
| Bumetanide | 13 | $653 | $50 |
| Bisoprolol | 11 | $633 | $58 |
| Fludrocortisone Acetate | 14 | $622 | $44 |
| Chlorthalidone | 21 | $544 | $26 |
| Hydrochlorothiazide | 109 | $314 | $3 |
| Atenolol | 72 | $266 | $4 |
| Simvastatin | 24 | $242 | $10 |
| Omeprazole | 28 | $229 | $8 |
| Cephalexin | 34 | $213 | $6 |
| Warfarin | 31 | $205 | $7 |
| Acetaminophen-Codeine | 27 | $199 | $7 |
| Benazepril | 14 | $160 | $11 |
| Clindamycin | 15 | $65 | $4 |
2021: 46 drugs
| Eliquis | 943 | $862,946 | $915 |
| Xarelto | 104 | $101,387 | $975 |
| Metoprolol | 1,019 | $26,324 | $26 |
| Pradaxa | 29 | $24,798 | $855 |
| Flecainide Acetate | 211 | $19,937 | $94 |
| Diltiazem 24hr Er (Cd) | 311 | $16,461 | $53 |
| Midodrine | 38 | $11,193 | $295 |
| Amiodarone | 158 | $9,043 | $57 |
| Atorvastatin | 241 | $4,352 | $18 |
| Carvedilol | 272 | $3,018 | $11 |
| Diltiazem | 92 | $2,379 | $26 |
| Potassium Chloride | 58 | $2,335 | $40 |
| Losartan | 184 | $2,236 | $12 |
| Ranolazine Er | 13 | $2,197 | $169 |
| Amlodipine Besylate | 270 | $2,117 | $8 |
| Nitroglycerin | 75 | $2,087 | $28 |
| Lisinopril | 244 | $2,063 | $8 |
| Propafenone | 21 | $1,980 | $94 |
| Diltiazem 24hr Er | 35 | $1,839 | $53 |
| Olmesartan Medoxomil | 22 | $1,795 | $82 |
| Ezetimibe | 21 | $1,659 | $79 |
| Isosorbide Mononitrate Er | 53 | $1,565 | $30 |
| Hydralazine | 83 | $1,524 | $18 |
| Spironolactone | 140 | $1,499 | $11 |
| Metoprolol | 124 | $1,332 | $11 |
| Digoxin | 13 | $1,166 | $90 |
| Furosemide | 162 | $1,136 | $7 |
| Rosuvastatin | 40 | $1,130 | $28 |
| Bumetanide | 14 | $944 | $67 |
| Pravastatin | 41 | $819 | $20 |
| Irbesartan | 13 | $804 | $62 |
| Pacerone | 18 | $789 | $44 |
| Warfarin | 58 | $779 | $13 |
| Valsartan | 17 | $608 | $36 |
| Fludrocortisone Acetate | 15 | $604 | $40 |
| Clopidogrel | 58 | $579 | $10 |
| Cartia Xt | 19 | $560 | $29 |
| Atenolol | 60 | $553 | $9 |
| Acetaminophen-Codeine | 61 | $551 | $9 |
| Tiadylt Er | 12 | $428 | $36 |
| Hydrochlorothiazide | 116 | $417 | $4 |
| Benazepril | 13 | $325 | $25 |
| Cephalexin | 65 | $219 | $3 |
| Omeprazole | 24 | $197 | $8 |
| Clindamycin | 53 | $171 | $3 |
| Simvastatin | 18 | $134 | $7 |
2020: 47 drugs
| Eliquis | 795 | $611,212 | $769 |
| Xarelto | 107 | $97,684 | $913 |
| Pradaxa | 39 | $28,377 | $728 |
| Metoprolol | 985 | $27,516 | $28 |
| Flecainide Acetate | 177 | $19,391 | $110 |
| Diltiazem 24hr Er (Cd) | 185 | $9,147 | $49 |
| Midodrine | 52 | $7,924 | $152 |
| Amiodarone | 145 | $4,558 | $31 |
| Diltiazem 24hr Er | 73 | $4,017 | $55 |
| Nitroglycerin | 32 | $2,909 | $91 |
| Carvedilol | 275 | $2,747 | $10 |
| Ezetimibe | 20 | $2,725 | $136 |
| Atorvastatin | 139 | $2,513 | $18 |
| Enoxaparin | 14 | $2,265 | $162 |
| Diltiazem | 85 | $2,072 | $24 |
| Lisinopril | 225 | $2,039 | $9 |
| Propafenone | 20 | $1,985 | $99 |
| Losartan | 147 | $1,875 | $13 |
| Verapamil Er | 16 | $1,638 | $102 |
| Amlodipine Besylate | 211 | $1,543 | $7 |
| Spironolactone | 143 | $1,521 | $11 |
| Potassium Chloride | 45 | $1,351 | $30 |
| Cartia Xt | 48 | $1,324 | $28 |
| Warfarin | 93 | $1,293 | $14 |
| Dilt-Xr | 26 | $1,280 | $49 |
| Olmesartan Medoxomil | 19 | $1,047 | $55 |
| Pravastatin | 33 | $1,042 | $32 |
| Hydralazine | 44 | $964 | $22 |
| Metoprolol | 87 | $904 | $10 |
| Bumetanide | 12 | $899 | $75 |
| Irbesartan | 17 | $877 | $52 |
| Rosuvastatin | 24 | $874 | $36 |
| Valsartan | 14 | $851 | $61 |
| Isosorbide Mononitrate Er | 26 | $849 | $33 |
| Clopidogrel | 58 | $786 | $14 |
| Furosemide | 127 | $726 | $6 |
| Fludrocortisone Acetate | 13 | $538 | $41 |
| Atenolol | 55 | $467 | $8 |
| Bisoprolol | 12 | $458 | $38 |
| Hydrochlorothiazide | 82 | $396 | $5 |
| Acetaminophen-Codeine | 46 | $310 | $7 |
| Benazepril | 13 | $278 | $21 |
| Cephalexin | 49 | $198 | $4 |
| Omeprazole | 19 | $177 | $9 |
| Simvastatin | 16 | $153 | $10 |
| Clindamycin | 15 | $75 | $5 |
| Lisinopril-Hydrochlorothiazide | 11 | $73 | $7 |
2019: 44 drugs
| Eliquis | 724 | $447,449 | $618 |
| Xarelto | 93 | $59,225 | $637 |
| Metoprolol | 1,118 | $32,869 | $29 |
| Pradaxa | 47 | $25,760 | $548 |
| Flecainide Acetate | 195 | $15,811 | $81 |
| Diltiazem 24hr Er (Cd) | 208 | $9,879 | $47 |
| Diltiazem 24hr Er | 136 | $5,879 | $43 |
| Amiodarone | 192 | $4,612 | $24 |
| Midodrine | 42 | $3,639 | $87 |
| Cartia Xt | 111 | $3,236 | $29 |
| Carvedilol | 354 | $2,946 | $8 |
| Atorvastatin | 188 | $2,897 | $15 |
| Dilt-Xr | 75 | $2,825 | $38 |
| Nadolol | 13 | $2,033 | $156 |
| Lisinopril | 241 | $1,924 | $8 |
| Diltiazem | 81 | $1,877 | $23 |
| Olmesartan Medoxomil | 13 | $1,835 | $141 |
| Amlodipine Besylate | 246 | $1,747 | $7 |
| Spironolactone | 206 | $1,583 | $8 |
| Bumetanide | 18 | $1,291 | $72 |
| Warfarin | 72 | $1,197 | $17 |
| Losartan | 124 | $1,188 | $10 |
| Propafenone | 28 | $1,176 | $42 |
| Rosuvastatin | 13 | $1,161 | $89 |
| Furosemide | 166 | $1,103 | $7 |
| Toprol Xl | 20 | $1,040 | $52 |
| Clopidogrel | 69 | $886 | $13 |
| Potassium Chloride | 38 | $840 | $22 |
| Isosorbide Mononitrate Er | 28 | $710 | $25 |
| Pravastatin | 39 | $686 | $18 |
| Verapamil Er | 17 | $659 | $39 |
| Nitroglycerin | 22 | $606 | $28 |
| Irbesartan | 11 | $570 | $52 |
| Metoprolol | 76 | $561 | $7 |
| Hydrochlorothiazide | 93 | $412 | $4 |
| Hydralazine | 27 | $348 | $13 |
| Acetaminophen-Codeine | 34 | $271 | $8 |
| Fludrocortisone Acetate | 12 | $270 | $23 |
| Atenolol | 34 | $267 | $8 |
| Benazepril | 11 | $251 | $23 |
| Cephalexin | 38 | $137 | $4 |
| Simvastatin | 11 | $121 | $11 |
| Enalapril Maleate | 11 | $86 | $8 |
| Clindamycin | 13 | $35 | $3 |
2018: 40 drugs
| Eliquis | 529 | $288,802 | $546 |
| Xarelto | 58 | $33,104 | $571 |
| Metoprolol | 1,086 | $31,376 | $29 |
| Pradaxa | 47 | $23,974 | $510 |
| Diltiazem 24hr Er (Cd) | 228 | $13,867 | $61 |
| Flecainide Acetate | 156 | $13,169 | $84 |
| Ranexa | 11 | $8,373 | $761 |
| Nadolol | 51 | $7,987 | $157 |
| Diltiazem 24hr Er | 106 | $4,144 | $39 |
| Dilt-Xr | 126 | $3,551 | $28 |
| Amiodarone | 126 | $3,302 | $26 |
| Cartia Xt | 127 | $3,136 | $25 |
| Atorvastatin | 153 | $2,625 | $17 |
| Carvedilol | 265 | $1,818 | $7 |
| Amlodipine Besylate | 245 | $1,754 | $7 |
| Midodrine | 12 | $1,668 | $139 |
| Ezetimibe | 14 | $1,603 | $114 |
| Toprol Xl | 27 | $1,468 | $54 |
| Spironolactone | 166 | $1,248 | $8 |
| Lisinopril | 205 | $1,242 | $6 |
| Furosemide | 181 | $1,008 | $6 |
| Diltiazem | 42 | $831 | $20 |
| Warfarin | 57 | $761 | $13 |
| Rosuvastatin | 13 | $656 | $50 |
| Clopidogrel | 45 | $590 | $13 |
| Digoxin | 11 | $589 | $54 |
| Isosorbide Mononitrate Er | 34 | $504 | $15 |
| Metoprolol | 77 | $484 | $6 |
| Losartan | 85 | $476 | $6 |
| Potassium Chloride | 13 | $411 | $32 |
| Bumetanide | 12 | $396 | $33 |
| Diltiazem 24hr Er (Xr) | 12 | $375 | $31 |
| Pravastatin | 22 | $364 | $17 |
| Nitroglycerin | 12 | $311 | $26 |
| Atenolol | 32 | $306 | $10 |
| Hydrochlorothiazide | 97 | $288 | $3 |
| Acetaminophen-Codeine | 21 | $227 | $11 |
| Benazepril | 13 | $207 | $16 |
| Isosorbide Mononitrate | 11 | $98 | $9 |
| Cephalexin | 23 | $82 | $4 |
2017: 31 drugs
| Eliquis | 385 | $188,514 | $490 |
| Xarelto | 47 | $27,546 | $586 |
| Metoprolol | 791 | $21,809 | $28 |
| Pradaxa | 14 | $8,641 | $617 |
| Flecainide Acetate | 130 | $8,369 | $64 |
| Diltiazem 24hr Er | 240 | $7,313 | $30 |
| Diltiazem 24hr Cd | 21 | $4,114 | $196 |
| Amiodarone | 67 | $3,369 | $50 |
| Olmesartan-Amlodipine-Hctz | 11 | $3,006 | $273 |
| Atorvastatin | 117 | $1,670 | $14 |
| Dilt-Xr | 53 | $1,431 | $27 |
| Carvedilol | 250 | $1,383 | $6 |
| Diltiazem | 50 | $1,292 | $26 |
| Valsartan | 21 | $1,139 | $54 |
| Diltiazem Er | 30 | $969 | $32 |
| Cartia Xt | 51 | $887 | $17 |
| Amlodipine Besylate | 170 | $866 | $5 |
| Chlorthalidone | 17 | $595 | $35 |
| Lisinopril | 130 | $553 | $4 |
| Furosemide | 154 | $550 | $4 |
| Spironolactone | 57 | $390 | $7 |
| Clopidogrel | 34 | $347 | $10 |
| Pravastatin | 29 | $328 | $11 |
| Spironolactone-Hctz | 11 | $288 | $26 |
| Klor-Con Sprinkle | 12 | $249 | $21 |
| Hydrochlorothiazide | 61 | $180 | $3 |
| Metoprolol | 34 | $148 | $4 |
| Irbesartan-Hydrochlorothiazide | 18 | $142 | $8 |
| Losartan | 23 | $105 | $5 |
| Levothyroxine | 11 | $104 | $9 |
| Cephalexin | 18 | $53 | $3 |
2016: 33 drugs
| Eliquis | 280 | $117,186 | $419 |
| Xarelto | 40 | $26,937 | $673 |
| Metoprolol | 471 | $14,296 | $30 |
| Diltiazem 24hr Er | 138 | $7,649 | $55 |
| Pradaxa | 16 | $7,285 | $455 |
| Amiodarone | 51 | $2,130 | $42 |
| Flecainide Acetate | 57 | $2,113 | $37 |
| Valsartan | 25 | $1,430 | $57 |
| Carvedilol | 172 | $1,205 | $7 |
| Atorvastatin | 67 | $1,169 | $17 |
| Digoxin | 26 | $1,152 | $44 |
| Dilt-Xr | 41 | $963 | $23 |
| Diltiazem 24hr Cd | 24 | $960 | $40 |
| Taztia Xt | 21 | $831 | $40 |
| Ramipril | 11 | $663 | $60 |
| Cartia Xt | 29 | $596 | $21 |
| Diltiazem | 25 | $457 | $18 |
| Pravastatin | 21 | $404 | $19 |
| Diltiazem Er | 12 | $403 | $34 |
| Lisinopril | 90 | $398 | $4 |
| Furosemide | 98 | $389 | $4 |
| Amlodipine Besylate | 89 | $361 | $4 |
| Potassium Chloride | 11 | $262 | $24 |
| Metoprolol | 55 | $234 | $4 |
| Valsartan-Hydrochlorothiazide | 13 | $205 | $16 |
| Warfarin | 19 | $200 | $11 |
| Clopidogrel | 11 | $187 | $17 |
| Spironolactone | 20 | $183 | $9 |
| Hydralazine | 12 | $169 | $14 |
| Losartan | 27 | $150 | $6 |
| Simvastatin | 17 | $100 | $6 |
| Cephalexin | 15 | $71 | $5 |
| Hydrochlorothiazide | 20 | $46 | $2 |
2015: 16 drugs
| Eliquis | 101 | $36,545 | $362 |
| Metoprolol | 164 | $6,182 | $38 |
| Diltiazem 24hr Er | 33 | $3,662 | $111 |
| Flecainide Acetate | 18 | $798 | $44 |
| Amiodarone | 25 | $792 | $32 |
| Dilt-Xr | 27 | $763 | $28 |
| Diltiazem Er | 18 | $624 | $35 |
| Atorvastatin | 19 | $364 | $19 |
| Cartia Xt | 14 | $357 | $25 |
| Carvedilol | 53 | $357 | $7 |
| Furosemide | 30 | $178 | $6 |
| Lisinopril | 36 | $174 | $5 |
| Spironolactone | 17 | $142 | $8 |
| Metoprolol | 15 | $126 | $8 |
| Amlodipine Besylate | 20 | $115 | $6 |
| Cephalexin | 14 | $48 | $3 |
Money from drug and device companies
$47 in 2025
| 2025 | 1 | 3 | None | $47 |
| 2024 | 2 | 4 | None | $78 |
| 2023 | 1 | 1 | None | $18 |
| 2022 | 3 | 3 | None | $179 |
| 2021 | 1 | 1 | None | $129 |
| 2020 | 2 | 6 | None | $557 |
| 2019 | 3 | 9 | None | $240 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Eliquis | $47 | 3 payments
|
See all 3 published payments
| Pfizer | Meals · 2025-03-06 | Eliquis | $14 |
| Pfizer | Meals · 2025-01-14 | Eliquis | $15 |
| Pfizer | Meals · 2025-01-08 | Eliquis | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $78
| Abbott Laboratories | Xience Skypoint | $64 | 3 payments
|
| Pfizer | Eliquis | $14 | 1 payment
|
2023: $18
| Pfizer | Eliquis | $18 | 1 payment
|
2022: $179
| Abbott Laboratories | Mitraclip | $143 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $20 | 1 payment
|
| Pfizer | Eliquis | $16 | 1 payment
|
2021: $129
| Abbott Laboratories | Mitraclip System | $129 | 1 payment
|
2020: $557
| Medtronic Vascular | Arctic Front | $544 | 5 payments
|
| Biosense Webster | Carto 3 System | $13 | 1 payment
|
2019: $240
| Amgen | Corlanor | $133 | 7 payments
|
| Medtronic Vascular | Arctic Front | $88 | 1 payment
|
| Abbott Laboratories | Heartmate | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1154492569
- Licence
- CA 10902, WI 60038-21California C10902: Deceased
- Group
- Community Foundation Medical Group · Fresno Community Hospital and Medical Center
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X)
- Mailing address
- 1313 E Herndon Ave, Suite 203, Fresno, CA, 93720
- NPI first listed
- 2006-11-10
- NPI last updated
- 2015-04-20
This is when the NPI record was last certified, not a medical board exam.